title: National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: evaluation of exemestane to prevent breast cancer in postmenopausal women.
authors.affiliation: Harvard Medical School, Boston, MA, USA. pgoss@partners.org
authors.forename: Paul E
authors.initials: PE
authors.lastname: Goss
authors.forename: Harriet
authors.initials: H
authors.lastname: Richardson
authors.forename: Rowan
authors.initials: R
authors.lastname: Chlebowski
authors.forename: Dianne
authors.initials: D
authors.lastname: Johnston
authors.forename: Gloria E
authors.initials: GE
authors.lastname: Sarto
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Maunsell
authors.forename: James N
authors.initials: JN
authors.lastname: Ingle
authors.forename: José E
authors.initials: JE
authors.lastname: Alés-Martinez
mesh_terms: D000730:Androstadienes / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000517:prevention & control; D002170:Canada; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D008875:Middle Aged; D017698:Postmenopause; D011788:Quality of Life; D012107:Research Design; D018570:Risk Assessment
chemical_list: D000730:Androstadienes; D000970:Antineoplastic Agents; D047072:Aromatase Inhibitors; C056516:exemestane